MCID: HPT003
MIFTS: 62

Hepatitis a

Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Rare diseases, Skin diseases

Aliases & Classifications for Hepatitis a

MalaCards integrated aliases for Hepatitis a:

Name: Hepatitis a 12 74 42 43 15 71
Viral Hepatitis, Type a 12
Viral Hepatitis a 12

Classifications:



External Ids:

Disease Ontology 12 DOID:12549
MeSH 43 D006506
NCIt 49 C3096
SNOMED-CT 67 40468003
ICD10 32 B15.0 B15.9
UMLS 71 C0019159

Summaries for Hepatitis a

MedlinePlus : 42 Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. Hepatitis is an inflammation of the liver. One type, hepatitis A, is caused by the hepatitis A virus (HAV). The disease spreads through contact with an infected person's stool. You can get it from Eating food made by an infected person who did not wash their hands after using the bathroom Drinking untreated water or eating food washed in untreated water Putting into your mouth a finger or object that came into contact with an infected person's stool Having close contact with an infected person, such as through sex or caring for someone who is ill Most people do not have any symptoms. If you do have symptoms, you may feel as if you have the flu. You may also have yellowish eyes and skin, called jaundice. A blood test will show if you have HAV. HAV usually gets better in a few weeks without treatment. However, some people can have symptoms for up to 6 months. Your doctor may suggest medicines to help relieve your symptoms. The hepatitis A vaccine can prevent HAV. Good hygiene can also help. Wash your hands thoroughly before preparing food, after using the toilet, or after changing a diaper. International travelers should be careful about drinking tap water. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Hepatitis a, also known as viral hepatitis, type a, is related to acute liver failure and fatty liver disease, and has symptoms including vomiting, fatigue and fever. An important gene associated with Hepatitis a is HAVCR1 (Hepatitis A Virus Cellular Receptor 1), and among its related pathways/superpathways are Innate Immune System and PI3K-Akt signaling pathway. The drugs Emtricitabine and Neomycin have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and kidney, and related phenotypes are cardiovascular system and homeostasis/metabolism

Disease Ontology : 12 A viral infectious disease that results in inflammation located in liver, has material basis in Hepatitis A virus, which is transmitted by ingestion of contaminated food or water, or transmitted by direct contact with an infected person. The infection has symptom fever, has symptom fatigue, has symptom loss of appetite, has symptom nausea, has symptom vomiting, has symptom abdominal pain, has symptom clay-colored bowel movements, has symptom joint pain, and has symptom jaundice.

Wikipedia : 74 Hepatitis A is an infectious disease of the liver caused by Hepatovirus A (HAV); it is a type of viral... more...

Related Diseases for Hepatitis a

Diseases in the Hepatitis family:

Hepatitis C Virus Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis B Hepatitis D
Autoimmune Hepatitis Hepatitis E
Autoimmune Hepatitis Type 2 Autoimmune Hepatitis Type 1

Diseases related to Hepatitis a via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 858)
# Related Disease Score Top Affiliating Genes
1 acute liver failure 32.6 GPT F2 ALB
2 fatty liver disease 31.9 TNF TLR4 INS GPT GGT1 ALB
3 hepatitis e 31.8 TNF TLR3 IFNG GPT GGT1 F2
4 cutaneous leishmaniasis 31.2 TNF TLR4 IL10 IFNG
5 hepatitis 31.1 TNF TICAM1 SEPSECS MAVS IKBKG IFNG
6 liver disease 31.1 TNF SEPSECS INS IFNA1 GPT GGT1
7 hepatitis d 31.0 IFNA1 GPT F2
8 acute kidney failure 30.9 HAVCR1 GPT F2 ALB
9 hepatic coma 30.9 GPT F2 ALB AFP
10 granulomatous hepatitis 30.8 TNF GPT ALB
11 acalculous cholecystitis 30.7 GPT F2 ALB
12 hepatic encephalopathy 30.6 TNF GPT F2 ALB AFP
13 poliomyelitis 30.6 TNF IL10 IFNG AFP
14 cholestasis 30.5 TNF GPT GGT1 F2 CYP3A4 ALB
15 acute kidney tubular necrosis 30.5 TNF HAVCR1 GGT1 ALB
16 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.5 INS IL10 IFNG
17 purpura 30.5 TNF IL10 IFNG F2
18 hepatorenal syndrome 30.5 HAVCR1 GPT F2 ALB AFP
19 diphtheria 30.5 TNF IFNG IFNA1 ALB
20 cholecystitis 30.5 TLR4 GPT F2 ALB
21 gastroenteritis 30.5 TNF IL10 IFNG IFNA1 ALB
22 syphilis 30.4 TNF IFNG GPT F2 ALB
23 tetanus 30.4 TNF IL10 IFNG ALB
24 viral hepatitis 30.3 TNF TLR4 TLR3 SEPSECS INS IL10
25 pancreatitis 30.3 TNF INS IL10 GGT1 ALB
26 liver cirrhosis 30.3 IFNA1 GPT GGT1 F2 CYP3A4 ALB
27 autoimmune hepatitis 30.3 TNF SEPSECS IL10 IFNA1 GPT GGT1
28 hyperthyroidism 30.3 TNF INS GPT ALB
29 drug-induced hepatitis 30.2 TNF SEPSECS GPT F2 ALB
30 alcohol use disorder 30.2 GPT GGT1 CYP3A4 ALB
31 thyroiditis 30.2 TNF INS IL10 IFNA1
32 autoimmune disease 30.2 TNF INS IL10 IFNG IFNA1 HAVCR2
33 chickenpox 30.1 TNF TLR3 IL10 IFNG IFNA1 ALB
34 alcoholic hepatitis 30.1 TNF TLR4 IL10 GPT GGT1 F2
35 pericardial effusion 30.1 GPT F2 ALB
36 mumps 30.1 TNF TLR3 IL10 IFNG IFNA1
37 neuritis 30.1 TNF IL10 IFNG
38 hyperuricemia 30.1 INS GPT GGT1 ALB
39 measles 30.1 TNF TLR4 TLR3 IFNG IFNA1
40 pharyngitis 30.1 TNF GPT ALB
41 meningoencephalitis 30.1 TNF TLR3 IL10 ALB
42 bilirubin metabolic disorder 30.1 GPT GGT1 F2 CYP3A4 ALB AFP
43 acute pancreatitis 30.1 TNF TLR4 INS IL10 GPT ALB
44 leptospirosis 30.1 TNF IL10 IFNG F2
45 japanese encephalitis 30.1 TNF TLR3 IFNA1
46 cryoglobulinemia 30.1 TNF IL10 IFNG IFNA1 GPT
47 eclampsia 30.0 TNF F2 ALB
48 infantile liver failure syndrome 1 30.0 GPT F2 ALB
49 typhoid fever 30.0 TNF TLR4 IFNG GPT GGT1 F2
50 newcastle disease 29.9 TNF TLR3 IFNA1

Graphical network of the top 20 diseases related to Hepatitis a:



Diseases related to Hepatitis a

Symptoms & Phenotypes for Hepatitis a

Symptoms:

12
  • vomiting
  • fatigue
  • fever
  • abdominal pain
  • jaundice
  • nausea
  • loss of appetite
  • joint pain
  • clay-colored bowel movements

UMLS symptoms related to Hepatitis a:


fever, pruritus, nausea and vomiting, abdominal pain, constipation, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas

MGI Mouse Phenotypes related to Hepatitis a:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.29 ALB F2 HAVCR2 IFNG IKBKG IL10
2 homeostasis/metabolism MP:0005376 10.27 AFP ALB F2 GGT1 IFNG IKBKG
3 hematopoietic system MP:0005397 10.26 F2 GGT1 HAVCR2 IFNG IKBKG IL10
4 immune system MP:0005387 10.25 ALB F2 GGT1 HAVCR2 IFNG IKBKG
5 digestive/alimentary MP:0005381 10.19 ALB F2 IFNG IKBKG IL10 INS
6 mortality/aging MP:0010768 10.17 AFP ALB F2 GGT1 HAVCR2 IFNG
7 integument MP:0010771 10.06 F2 GGT1 IFNG IKBKG IL10 INS
8 liver/biliary system MP:0005370 10.02 AFP ALB IFNG IKBKG IL10 INS
9 muscle MP:0005369 9.86 ALB IFNG IL10 INS MAVS TLR3
10 neoplasm MP:0002006 9.81 AFP ALB IFNG IKBKG IL10 TICAM1
11 reproductive system MP:0005389 9.65 AFP F2 GGT1 IFNG IKBKG IL10
12 respiratory system MP:0005388 9.23 F2 IFNG IL10 MAVS TICAM1 TLR3

Drugs & Therapeutics for Hepatitis a

Drugs for Hepatitis a (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 433)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
2
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
3
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
4
Ezetimibe Approved Phase 4 163222-33-1 150311
5
glycyrrhizin Approved, Experimental Phase 4 1405-86-3 3495
6
Rifampicin Approved Phase 4 13292-46-1 5381226 5458213
7
Pyrazinamide Approved, Investigational Phase 4 98-96-4 1046
8
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
9
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
10
Acetylcarnitine Approved, Investigational Phase 4 3040-38-8 7045767
11
Nitazoxanide Approved, Investigational, Vet_approved Phase 4 55981-09-4 41684
12
Methadone Approved Phase 4 76-99-3 4095
13
Milk thistle Approved, Experimental, Investigational Phase 4 65666-07-1
14
Nelfinavir Approved Phase 4 159989-64-7 64143
15
Zidovudine Approved Phase 4 30516-87-1 35370
16
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
17
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
18
Metformin Approved Phase 4 657-24-9 14219 4091
19
Citalopram Approved Phase 4 59729-33-8 2771
20
Losartan Approved Phase 4 114798-26-4 3961
21
Cobicistat Approved Phase 4 1004316-88-4
22
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
23
Simethicone Approved Phase 4 8050-81-5
24
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
25
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 27284 23925
26
Colchicine Approved Phase 4 64-86-8 2833 6167
27
Adalimumab Approved Phase 4 331731-18-1 16219006
28
Etanercept Approved, Investigational Phase 4 185243-69-0
29
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
30
Sargramostim Approved, Investigational Phase 4 83869-56-1, 123774-72-1
31
Lenograstim Approved, Investigational Phase 4 135968-09-1
32
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
33
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
34
Nevirapine Approved Phase 4 129618-40-2 4463
35
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
36
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
37
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
38
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
39
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
40 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
41
Mycophenolic acid Approved Phase 4 24280-93-1 446541
42
Interferon alfacon-1 Approved, Investigational Phase 4 118390-30-0 9554198
43
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
44
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
45
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
46
tannic acid Approved Phase 4 1401-55-4
47
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
48
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
49
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
50
Methylcobalamin Approved, Investigational Phase 4 13422-55-4

Interventional clinical trials:

(show top 50) (show all 2615)
# Name Status NCT ID Phase Drugs
1 Prophylactic Use of Entecavir to Reduce Hepatitis Flare in Highly Viremic HBV Patients With Active Tuberculosis Receiving Anti-tuberculous Treatment Unknown status NCT01724723 Phase 4 entecavir (BARACLUDE®)
2 Comparative Immunogenicity Study of Two Live Attenuated Hepatitis A Vaccines Unknown status NCT03231605 Phase 4
3 A Study Comparing the Effectiveness of Two Different Vaccination Schedules of the Combined Hepatitis A and B Vaccine(Twinrix Adult1440/20) Unknown status NCT00216229 Phase 4
4 Immune Response to Pneumococcal Conjugate Vaccine in Adults Receiving Hepatitis A Vaccine at the Same Time Unknown status NCT01926860 Phase 4
5 Active Drug Comparative Trial to Evaluate the Antiviral Activity and Safety in Chronic Hepatitis B Patients Unknown status NCT02588937 Phase 4 EntecaBell ODT. 0.5mg;Baraclude Tab. 0.5mg
6 Efficacy and Safety of Daclatasvir Plus Asunaprevir Treatment in Patients With Chronic Hepatitis C : Prospective Cohort Study Unknown status NCT02639585 Phase 4 Daclinza and Sunvepra
7 Cellular Immunity in Adult Hepatitis B-vaccinated Serologic Non-responders Unknown status NCT01451801 Phase 4
8 Study to Identify Eligible Subjects Using Response Guided Therapy-Stopping Rule for Treatment of Pegylated Interferon Alfa 2a(Pegasys®) in the Korean Chronic Hepatitis B(CHB) Adults. Unknown status NCT02822547 Phase 4 Peginterferon alfa-2a
9 PhaseIVstudy to Evaluate the Non-inferiority of Cavir®Tab. in Terms of Hepatitis B Virus(HBV)DNA Undetectability Comparing Baraclude® Tab. in Hepatitis B e Antigen(HBeAg)(+) Chronic Hepatitis B Patients Treated With Long-term Baraclude® Tab Unknown status NCT02523547 Phase 4 Cavir;Baraclude
10 A 3-year, Open-lable, Multi-center Extension Trial of Entecavir Therapy for Patients Previously Treated in Dragon Study Unknown status NCT01829685 Phase 4 Entecavir, Adefovir
11 Efficacy of Long-term Telbivudine Treatment on Histological Improvements in Patients With Chronic Hepatitis B (EFFORT Further Extension Study) Unknown status NCT02826070 Phase 4 Telbivudine;Adefovir dipivoxil
12 Investigator Initiated Study of Thymosin in HBV-related HCC Unknown status NCT02281266 Phase 4 thymalfasin;nucleoside analog (suggest to use entecavir)
13 Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients Unknown status NCT02327702 Phase 4 Emtricitabine
14 Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis Unknown status NCT01998620 Phase 4 Ademetionine 2;Ademetionine 1;Ademetionine 3
15 Efficacy and Safety of S-adenosyl-l-methionine in Treatment of Alcoholic Hepatitis With Cholestasis Unknown status NCT02024295 Phase 4 Ademethionine;Polyene Phosphatidyl choline;Ademethionine
16 Efficacy and Safety of Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With Chronic Hepatitis B Who Have Resistant Mutants to Lamivudine and Show Suboptimal Response to Combination of Lamivudine Plus Adefovir or Adefovir Monotherapy Unknown status NCT02482272 Phase 4 Lamivudine;Adefovir;Entecavir
17 A Multi-center, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Generic Entecavir Monotherapy or in Combination With Adefovir for Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy Unknown status NCT01341743 Phase 4 Entecavir;Entecavir, Adefovir;Entecavir, Adefovir
18 Efficacy of Antiviral Therapy With Lamivudine or Entecavir After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma Unknown status NCT00768157 Phase 4 antiviral treatment (lamivudine or entecavir)
19 Clinical Study of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B Unknown status NCT01380951 Phase 4 telbivudine
20 Effects of Short-term Atorvastatin Treatment on Vaccination Efficacy in Nonresponder Persons to Hepatitis B Vaccine Unknown status NCT01548326 Phase 4 Atorvastatin;placebo
21 A Randomized, Multi-center, Phase IV Open-label Study Evaluating the Antiviral Efficacy of Addition of Vitamin D in Patients With Treatment Naïve Chronic Hepatitis C Receiving Peginterferon Alfa-2a Plus Ribavirin Unknown status NCT01439776 Phase 4
22 A Multi-center, Open Label, Randomized Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Capsule Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients Unknown status NCT01436539 Phase 4 Adefovir Dipivoxil and polyene phosphatidylcholine;Adefovir Dipivoxil
23 Hepatitis C in Renal Transplant Recipients - Safety and Efficacy of a Conversion of Immunosuppression to High-dose Cyclosporine A and Its Impact on Hepatitis C Virus-replication, Parameters of Liver Function and Glucose Tolerance. An Open Label Trial. Unknown status NCT02108301 Phase 4 tacrolimus-cyclosporine A
24 Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients Unknown status NCT02327676 Phase 4 Emtricitabine
25 Immunogenicity and Safety of High-dose Hepatitis B Vaccine Among Drug Users: a Randomized, Controlled Trial Unknown status NCT02959775 Phase 4
26 Grazoprevir/Elbasvir for Treatment of Hepatitis C Virus Genotype 4 Post Kidney Transplant Unknown status NCT03359746 Phase 4 Grazoprevir/Elbasvir
27 A Randomised, Open-label Clinical Trial Assessing the Efficacy and Safety of Mycophenolate Mofetil Versus Azathioprine for Induction of Remission in Treatment Naive Autoimmune Hepatitis Unknown status NCT02900443 Phase 4 Mycophenolate mofetil;Azathioprine
28 The Efficacy and Safety of the Anti Hepatitis B Placenta Transfer Factor Injection in the Treatment of HBeAg Positive Chronic Hepatitis B, Randomized, Double Blind, Placebo Controlled, Multi Center Clinical Trial Unknown status NCT02412319 Phase 4 Anti-HBV placenta transfer factor injection
29 Treatment of Chronic Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels With Peginterferon α-2a (40 kDa) Plus Ribavirin Unknown status NCT00575627 Phase 4 Peg-Interferon alpha2a plus Ribavirin
30 Immunogenicity and Reactogenicity of 10-valent Pneumococcal Conjugate Vaccine (PCV10) in Children Aged 12-59 Months Unknown status NCT01028326 Phase 4
31 Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma Unknown status NCT01765231 Phase 4 Entecavir prophylaxis;Observation arm
32 Comparison of Antiviral Efficacy of Entecavir Monotherapy and Combination Treatment With Poly IC for Chronic Hepatitis B Unknown status NCT02532413 Phase 4 Poly IC;Entecavir
33 A Study of Efficacy and Safety of Telbivudine in Pregnancy for the Prevention of Perinatal Transmission of Hepatitis B Virus Infection Unknown status NCT00939068 Phase 4 Telbivudine
34 A Multi Center, Phase IIIb Study to Evaluate the Efficacy of Response Guided Therapy Using Quantitative HBsAg Measurement in Patient With HBeAg Positive Chronic Hepatitis B: Unknown status NCT01456312 Phase 4 Peginterferon alfa-2a;Entecavir
35 Entecavir for Patients With Decompensated HBV-Related Cirrhosis:a Prospective Randomized Controlled Trial Unknown status NCT00663182 Phase 4 Entecavir
36 A Pilot Study to Assess the Efficacy and Safety of Folic Acid and/or Vitamin B Complex on Hepatitis C Infected Patients Treated With Pegylated Interferon and Ribavirin. Unknown status NCT02150291 Phase 4 Neurobion;placebo
37 A Randomized, Open-label, Multi-center Clinical Trial to Evaluate Addition of Peginterferon Alfa-2a to CHB Patients Treated With NAs and Achieved HBV DNA<15 IU/ml、HBeAg<100 PEIU/ml、HBsAg Positive and HBsAg<1500 IU/ml. Unknown status NCT02894918 Phase 4 Peginterferon alfa-2a
38 Emtricitabine for Naive Chinese Chronic Hepatitis B Patients Unknown status NCT02327663 Phase 4 Emtricitabine
39 Efficacy and Safety of Combination Therapy With Entecavir, Peginterferon Alfa-2b and Immunomodulators in Nucleoside or Nucleotide Analogue (NA)-Suppressed Chronic Hepatitis B Patients Unknown status NCT03332329 Phase 4 Entecavir;Granulocyte Macrophage Colony Stimulating Factor;Y peginterferon alfa-2b;HBV vaccine
40 Investigation on Antiviral Therapy of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B Patients Based on Detection of Interferon Gene Mutation and Interferon Receptor Unknown status NCT02973646 Phase 4 Entecavir or Tenofovir;Peginterferon Alfa-2B
41 Immunogenicity and Persistence of Intramuscular High Dose Recombinant Hepatitis B Vaccine in Hemodialysis Patients in China: a Multicenter Randomized Controlled Trial Unknown status NCT02963714 Phase 4
42 Analysis of Proximal Renal Tubular Function of "Real World" Chronic Hepatitis B (CHB) Patients Who Are Suppressed on TDF and Switched to TAF Unknown status NCT02957994 Phase 4 Tenofovir alafenamide fumarate
43 Toward Elimination of Hepatitis C Virus (HCV): A Pilot Study Combining HCV and Addiction Treatment of Young Suburban Heroin Users (SHU) That Addresses Barriers to Care Unknown status NCT03364725 Phase 4 Glecaprevir-pibrentasvir
44 Immunogenicity and Persistence of Intramuscular High Dose Recombinant Hepatitis B Vaccine in HIV-infected Adults in China Unknown status NCT03316807 Phase 4
45 A Prospective, Randomized, Controlled Clinical Trial to Evaluate the Role of Peg-IFN Alfa-2a in Reducing RelapSe Rate in Patients With Hepatitis B e Antigen(HBeAg)-nEgative Chronic Hepatitis B After Discontinuation of NUC Therapy Unknown status NCT02594293 Phase 4 PegIFN alfa-2a
46 Sustained Off-treatment Response After HBeAg Loss in HBeAg-Pos Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues Unknown status NCT01911156 Phase 4 Continue NA treatment;Discontinue NA Treatment
47 Immunologic Response of Hepatitis B Single Dose Versus 3-dose Series in Previously Vaccinated HIV-infected Adults at Maharaj Nakorn Chiang Mai Hospital: A Randomized Controlled Trial Unknown status NCT03219203 Phase 4
48 Efficacies of Entecavir Add on HBeAg Negative Chronic Hepatitis B Patients With HBV DNA Load ≥1000 Copies/ml After 3 Months of Peginterferon Alpha 2a Treatment Unknown status NCT02365402 Phase 4 Entecavir
49 Project to Evaluate Hepatitis B Vaccine-induced Immunity Among US-born Adolescents Who Received Hepatitis B Primary Vaccination Series During Early Childhood Unknown status NCT01341275 Phase 4
50 The Response and Outcomes of Pegylated Interferon Plus Ribavirin Combination Therapy for Chronic Hepatitis C Patients Concomitant With Hepatocellular Carcinoma Unknown status NCT00834860 Phase 4 peginterferon alpha-2a and ribavirin

Search NIH Clinical Center for Hepatitis a

Cochrane evidence based reviews: hepatitis a

Genetic Tests for Hepatitis a

Anatomical Context for Hepatitis a

The Foundational Model of Anatomy Ontology organs/tissues related to Hepatitis a:

19
Liver

MalaCards organs/tissues related to Hepatitis a:

40
Liver, Testes, Kidney, T Cells, Bone, Lung, Skin

Publications for Hepatitis a

Articles related to Hepatitis a:

(show top 50) (show all 12176)
# Title Authors PMID Year
1
Seroepidemiology of hepatitis viruses, measles, mumps, rubella and varicella among healthcare workers and students: Should we screen before vaccination? 42 61
32113699 2020
2
Status of adult immunity to hepatitis A virus in healthcare workers from a tertiary care hospital in north India. 42 61
31939396 2019
3
Booster immunity - diagnosis of chronic hepatitis B viral infection. 42 61
32040457 2019
4
Exosomes cloak the virion to transmit Enterovirus 71 non-lytically. 61
31885311 2020
5
HAV detection from milk-based products containing soft fruits: Comparison between four different extraction methods. 61
32454367 2020
6
Heat sensitization of hepatitis A virus and Tulane virus using grape seed extract, gingerol and curcumin. 61
32336357 2020
7
Early SARS-CoV-2 outbreak detection by sewage-based epidemiology. 61
32417555 2020
8
Hepatitis A takes hold in the community. 61
32558785 2020
9
Hepatitis A takes hold in the community. 61
32558786 2020
10
Effect of duck hepatitis A virus genotype 3 infection on glucose metabolism of Pekin ducklings and underlying mechanism. 61
32339622 2020
11
Public Health Role of Academic Medical Center in Community Outbreak of Hepatitis A, San Diego County, California, USA, 2016-2018. 61
32568038 2020
12
Architect i2000 SR has improved turnaround time for infectious disease serology testing over Vitros ECiQ. 61
32340767 2020
13
Immunity to hepatitis A among men who have sex with men attending a large sexual health clinic in Melbourne, Australia, 2012-2018. 61
32169881 2020
14
Estimated Additional Number of Adults in HIV Care Who have an Indication for Hepatitis A Vaccination Following 2020 US Guideline Update. 61
32568767 2020
15
Global Epidemiology of Viral Hepatitis. 61
32389357 2020
16
Motivations, facilitators and barriers to accessing hepatitis C treatment among people who inject drugs in two South African cities. 61
32522210 2020
17
Homelessness and Hepatitis A-San Diego County, 2016-2018. 61
31412358 2020
18
Hepatitis A: Epidemiology, Natural History, Unusual Clinical Manifestations, and Prevention. 61
32389358 2020
19
Missed Opportunities for Hepatitis A Vaccination Among MSM Initiating PrEP. 61
31720939 2020
20
Human Gene Sequences in SARS-CoV-2 and Other Viruses. 61
32503822 2020
21
Ongoing transmission of Entamoeba histolytica among newly diagnosed people living with HIV in Taiwan, 2009-2018. 61
32530918 2020
22
Can economic indicators predict infectious disease spread? A cross-country panel analysis of 13 European countries. 61
31291826 2020
23
Vaccination coverage rates of military personnel worldwide: a systematic review of the literature. 61
32561973 2020
24
Factors associated with anti-hepatitis A virus immunoglobulin G seropositivity among Korean workers: a cross-sectional study. 61
32513893 2020
25
Hepatitis A Outbreak with the Concurrence of Salmonella Typhi and Salmonella Poona Infection in Children of Urban Vellore, South India. 61
32228778 2020
26
Factors associated with hepatitis A virus infection among HIV-positive patients before and after implementation of a hepatitis A virus vaccination program at a medical centre in central Taiwan. 61
32571474 2020
27
Alginate-coated chitosan nanoparticles act as effective adjuvant for hepatitis A vaccine in mice. 61
32114177 2020
28
Acute liver failure in a Mexican family infected with hepatitis A virus. 61
31526632 2020
29
First evidence for continuous circulation of hepatitis A virus subgenotype IIA in Central Africa. 61
32564517 2020
30
Exosome mimicry by a HAVCR1-NPC1 pathway of endosomal fusion mediates hepatitis A virus infection. 61
32541946 2020
31
Immunogenicity of the hepatitis A vaccine 20 years after infant immunization. 61
32535018 2020
32
Sexual behaviour and poor hygiene are related to recent hepatitis a virus community outbreaks. 61
32450702 2020
33
Poor response to hepatitis A vaccination in hematopoietic stem cell transplant recipients. 61
32034983 2020
34
Development of a live attenuated duck hepatitis A virus type 3 vaccine (strain SD70). 61
32446833 2020
35
Liver transplant for alcoholic hepatitis: a current clinical overview. 61
32511039 2020
36
Application of median lethal concentration (LC50) of pathogenic microorganisms and their antigens in vaccine development. 61
32539814 2020
37
Human genetic basis of fulminant viral hepatitis. 61
32285199 2020
38
Reactive Polymer Targeting dsRNA as Universal Virus Detection Platform with Enhanced Sensitivity. 61
32233463 2020
39
Identification and genome characterization of a novel picornavirus from ducks in China. 61
32524264 2020
40
Prevalence of Hepatitis B Virus Infection Among US Adults Aged 20-59 Years With a History of Injection Drug Use: National Health and Nutrition Examination Survey, 2001-2016. 61
31350875 2020
41
Functions of human liver CD69+CD103-CD8+ T cells depend on HIF-2α activity in healthy and pathologic livers. 61
31987989 2020
42
Development and evaluation of an indirect ELISA based on recombinant structural protein VP2 to detect antibodies against duck hepatitis A virus. 61
32485472 2020
43
Immunogenicity, long term protection and safety of subcutaneous administration of hepatitis A vaccine in patients with hemophilia and other bleeding disorders: A randomized study. 61
32376110 2020
44
Polyvalent Human Immune Globulin: A Prospective, Open-Label Study Assessing Anti-Hepatitis A Virus (HAV) Antibody Levels, Pharmacokinetics, and Safety in HAV-Seronegative Healthy Subjects. 61
32301062 2020
45
Short-term immunogenicity and safety of hepatitis-A and varicella vaccines in HIV-exposed uninfected and HIV-unexposed South African children. 61
32307279 2020
46
Inactivation by osmotic dehydration and air drying of Salmonella, Shiga toxin-producing Escherichia coli, Listeria monocytogenes, hepatitis A virus and selected surrogates on blueberries. 61
31962220 2020
47
Prolonged cholestasis after acute viral hepatitis: successfully treated with oral steroid. 61
32444440 2020
48
High expression of immune checkpoints is associated with the TIL load, mutation rate and patient survival in colorectal cancer. 61
32468013 2020
49
Strategies for hepatitis B booster vaccination among children: an 8-year prospective cohort study. 61
32429793 2020
50
Assessment of ISO Method 15216 to Quantify Hepatitis E Virus in Bottled Water. 61
32414206 2020

Variations for Hepatitis a

Expression for Hepatitis a

Search GEO for disease gene expression data for Hepatitis a.

Pathways for Hepatitis a

Pathways related to Hepatitis a according to GeneCards Suite gene sharing:

(show all 45)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.03 TNF TLR4 TLR3 TICAM1 MAVS INS
2
Show member pathways
12.96 TNF TLR4 TLR3 TICAM1 INS IKBKG
3
Show member pathways
12.93 TNF TLR4 TLR3 TICAM1 IKBKG IFNA1
4
Show member pathways
12.83 TNF INS IL10 IFNG IFNA1
5 12.76 TNF TLR3 TICAM1 MAVS IKBKG IFNG
6
Show member pathways
12.7 TNF TLR4 TLR3 TICAM1 IKBKG IFNA1
7
Show member pathways
12.7 TNF TLR4 TLR3 TICAM1 MAVS IL10
8
Show member pathways
12.59 TNF TLR4 IL10 IKBKG IFNG
9
Show member pathways
12.58 TNF IL10 IKBKG IFNG F2
10
Show member pathways
12.57 TNF TLR4 TLR3 TICAM1 MAVS IKBKG
11
Show member pathways
12.56 TNF TLR4 TICAM1 IL10 IKBKG IFNG
12
Show member pathways
12.55 TLR3 TICAM1 MAVS IKBKG IFNA1
13
Show member pathways
12.54 TNF MAVS IKBKG IFNG IFNA1
14
Show member pathways
12.29 TLR4 TLR3 TICAM1 IKBKG
15 12.27 TNF TLR4 IKBKG F2
16
Show member pathways
12.27 TNF TLR4 TLR3 TICAM1 IKBKG IFNG
17
Show member pathways
12.24 TNF TLR4 TLR3 TICAM1 IKBKG
18
Show member pathways
12.24 TNF INS IFNG GGT1 F2 ALB
19
Show member pathways
12.23 TNF TLR4 IL10 IKBKG IFNG
20 12.2 TNF TLR4 IL10 IFNG IFNA1
21 12.19 TNF TLR4 TLR3 IFNG
22
Show member pathways
12.19 TNF TLR4 IKBKG IFNG
23 12.14 TNF TLR4 TICAM1 MAVS IKBKG IFNA1
24
Show member pathways
12.03 TNF TLR4 TLR3 TICAM1 IFNG IFNA1
25 11.99 TNF IL10 IFNG GYPA
26 11.95 TNF TLR4 TICAM1 IL10 IKBKG
27 11.93 TNF TLR4 TICAM1 IKBKG
28 11.91 TNF TLR4 IL10 IFNG
29 11.9 TNF TLR4 TICAM1 IKBKG
30
Show member pathways
11.88 TNF TLR4 TLR3 IL10 IFNG
31 11.84 TNF TLR3 TICAM1 MAVS IL10 IKBKG
32 11.77 TNF IL10 IFNG
33 11.76 TNF TLR4 TICAM1 IL10
34 11.73 TNF IL10 IFNG
35 11.59 TNF TLR4 IKBKG
36
Show member pathways
11.56 TNF IKBKG IFNG
37 11.52 TNF TLR4 IFNG
38 11.49 TNF IFNG CYP3A4
39 11.45 INS F2 ALB AFP
40 11.38 TNF IL10 IFNG
41
Show member pathways
11.37 TNF IL10 IFNG
42 11.35 TNF TLR4 IL10
43 11.26 TNF IL10 IFNG
44 11.05 TLR4 TLR3 TICAM1 IKBKG
45 11.05 TNF TLR4 IL10 IFNG GYPA

GO Terms for Hepatitis a

Cellular components related to Hepatitis a according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.36 TNF TLR3 INS IL10 IFNG IFNA1

Biological processes related to Hepatitis a according to GeneCards Suite gene sharing:

(show top 50) (show all 64)
# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 10.18 TLR4 TLR3 TICAM1 MAVS IKBKG HAVCR2
2 positive regulation of gene expression GO:0010628 10.14 TNF TLR4 TLR3 TICAM1 INS IFNG
3 immune response GO:0006955 10.13 TNF TLR4 IL10 IKBKG IFNG
4 inflammatory response GO:0006954 10.09 TNF TLR4 TLR3 TICAM1 IKBKG HAVCR2
5 defense response to bacterium GO:0042742 10.07 TNF TLR4 TLR3 MAVS IL10
6 cellular protein metabolic process GO:0044267 10.03 INS F2 ALB AFP
7 positive regulation of protein phosphorylation GO:0001934 10.02 TNF MAVS IFNG F2
8 defense response to virus GO:0051607 10.02 TLR3 TICAM1 MAVS IFNG IFNA1
9 response to lipopolysaccharide GO:0032496 10.01 TLR4 TICAM1 IL10 GGT1
10 cellular response to lipopolysaccharide GO:0071222 10 TNF TLR4 TICAM1 IL10 HAVCR2
11 response to virus GO:0009615 9.97 TNF TLR3 IKBKG IFNG
12 positive regulation of inflammatory response GO:0050729 9.93 TNF TLR4 TLR3 IFNG
13 positive regulation of JNK cascade GO:0046330 9.91 TNF TLR4 TLR3
14 apoptotic signaling pathway GO:0097190 9.91 TNF TLR4 TLR3 TICAM1
15 humoral immune response GO:0006959 9.9 TNF IFNG IFNA1
16 negative regulation of tumor necrosis factor production GO:0032720 9.89 TLR4 IL10 HAVCR2
17 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.89 TNF TLR4 TLR3 HAVCR2
18 positive regulation of interferon-gamma production GO:0032729 9.88 TNF TLR4 HAVCR2
19 extrinsic apoptotic signaling pathway GO:0097191 9.88 TNF TLR3 IFNG
20 lipopolysaccharide-mediated signaling pathway GO:0031663 9.88 TNF TLR4 TICAM1
21 positive regulation of interleukin-6 production GO:0032755 9.87 TNF TLR4 TLR3 TICAM1
22 response to exogenous dsRNA GO:0043330 9.86 TLR3 TICAM1 IFNA1
23 positive regulation of cytokine production GO:0001819 9.86 TNF TLR3 HAVCR2
24 positive regulation of JAK-STAT cascade GO:0046427 9.86 TNF IL10 F2
25 positive regulation of tumor necrosis factor production GO:0032760 9.86 TLR4 TLR3 TICAM1 MAVS
26 negative regulation of interferon-gamma production GO:0032689 9.85 TLR4 IL10 HAVCR2
27 microglial cell activation GO:0001774 9.85 TNF TLR3 IFNG
28 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.85 TNF TLR4 TLR3 TICAM1 MAVS IKBKG
29 positive regulation of interferon-beta production GO:0032728 9.84 TLR4 TLR3 MAVS
30 positive regulation of nitric oxide biosynthetic process GO:0045429 9.84 TNF TLR4 TICAM1 IFNG
31 positive regulation of interleukin-12 production GO:0032735 9.82 TLR4 TLR3 IFNG
32 positive regulation of tumor necrosis factor secretion GO:1904469 9.82 MAVS IFNG HAVCR2
33 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.81 TNF TLR4 TICAM1
34 positive regulation of interleukin-6 secretion GO:2000778 9.81 TNF TLR4 MAVS IFNG
35 necroptotic process GO:0070266 9.8 TLR4 TLR3 TICAM1
36 positive regulation of macrophage activation GO:0043032 9.8 TLR4 IL10 HAVCR2
37 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.8 TNF TLR4 TLR3 TICAM1 INS IKBKG
38 negative regulation of interleukin-6 production GO:0032715 9.78 TNF TLR4 IL10 HAVCR2
39 macrophage activation involved in immune response GO:0002281 9.76 TICAM1 IFNG HAVCR2
40 positive regulation of cytokine secretion GO:0050715 9.76 TNF INS IL10 IFNG
41 toll-like receptor 3 signaling pathway GO:0034138 9.75 TLR3 TICAM1 HAVCR2
42 negative regulation of amyloid-beta clearance GO:1900222 9.73 TNF IFNG
43 positive regulation of interleukin-1 beta biosynthetic process GO:0050725 9.73 TNF IFNG
44 necroptotic signaling pathway GO:0097527 9.73 TNF TLR3
45 TRIF-dependent toll-like receptor signaling pathway GO:0035666 9.73 TLR4 TLR3 TICAM1 IKBKG
46 endothelial cell apoptotic process GO:0072577 9.72 TNF IL10
47 positive regulation of myeloid dendritic cell cytokine production GO:0002735 9.72 TICAM1 MAVS
48 positive regulation of MHC class II biosynthetic process GO:0045348 9.72 TLR4 IL10 IFNG
49 negative regulation of cytokine production involved in immune response GO:0002719 9.71 TNF IL10
50 negative regulation of cytokine secretion involved in immune response GO:0002740 9.71 TNF IL10

Molecular functions related to Hepatitis a according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.92 TNF IL10 IFNG IFNA1

Sources for Hepatitis a

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....